Bio-Techne Full Year 2024 Earnings: EPS Misses Expectations
Bio-Techne (NASDAQ:TECH) Full Year 2024 Results
Key Financial Results
Revenue: US$1.16b (up 2.0% from FY 2023).
Net income: US$168.1m (down 41% from FY 2023).
Profit margin: 14% (down from 25% in FY 2023). The decrease in margin was driven by higher expenses.
EPS: US$1.07 (down from US$1.81 in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Bio-Techne EPS Misses Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 6.1%.
The primary driver behind last 12 months revenue was the Protein Sciences segment contributing a total revenue of US$830.9m (72% of total revenue). The largest operating expense was General & Administrative costs, amounting to US$428.5m (71% of total expenses). Explore how TECH's revenue and expenses shape its earnings.
Looking ahead, revenue is forecast to grow 8.2% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Life Sciences industry in the US.
Performance of the American Life Sciences industry.
The company's shares are down 3.0% from a week ago.
Risk Analysis
You should learn about the 1 warning sign we've spotted with Bio-Techne.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.